Clinical and Genomic Characterization of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV-2) Infections in mRNA Vaccinated Health Care Personnel in New York City
Author(s) -
Elizabeth Robilotti,
Karissa Whiting,
Anabella Lucca Bianchi,
Chester Poon,
Rebecca Guest,
Tracy McMillen,
Krupa Jani,
Alexander Solovyov,
Suzanne Kelson,
Kevin P. Browne,
Scott Freeswick,
Tobias M. Hohl,
Deborah Korenstein,
Denis Ruchnewitz,
Michael Lässig,
Marta Łuksza,
Benjamin Greenbaum,
Venkatraman Seshan,
N. Esther Babady,
Mini Kamboj
Publication year - 2021
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/ciab886
Subject(s) - medicine , covid-19 , coronavirus , virology , betacoronavirus , sars virus , respiratory system , immunology , outbreak , infectious disease (medical specialty) , disease
Vaccine-induced clinical protection against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) variants is an evolving target. There are limited genomic level data on SARS CoV-2 breakthrough infections and vaccine effectiveness (VE) since the global spread of the B.1.617.2 (Delta) variant.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom